Hepatitis B Treatment
OLX703A targets a sequence that is common to all viral transcripts of hepatitis B virus (HBV),
with the aim of reducing serum levels of HBV surface antigen.
It also has the advantage of targeting sequences that are conserved in over 90% of 10 genotypes,
making the drug applicable to a diverse range of patients, including those resistant to existing antiviral drugs.
Target RNA: HBV transcripts
Administration Route: Subcutaneous Injection
Hepatitis B, a type of viral hepatitis, is transmitted through blood or body fluids. When a cell is infected, it triggers an immune response to eliminate the virus, often causing liver inflammation. The process can lead to cirrhosis and, ultimately, liver cancer. The viral genome is stored in infected liver cells as cccDNA (covalently closed circular DNA), in which the disease can persist chronically even after antiviral treatment.
- Efficacy verified in AAV-HBV mouse model
- 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)